About Soliris®
Soliris is the first and only approved medication for the treatment of patients with PNH to reduce hemolysis
By blocking complement (one of your body’s defense systems), Soliris reduces hemolysis, the underlying cause of complications, and therefore improves symptoms and reduces the major health problems associated with PNH.1 In clinical trials, patients who received Soliris experienced the following benefits1,2:
- Reduced chronic hemolysis in all patients — immediate and long term
- Fewer blood clots (thrombotic events), as compared to the same time period prior to starting Soliris
- Significant improvements in fatigue levels and overall quality of life
- Significant reduction in the need for transfusions
In clinical trials, the majority of patients received concomitant anticoagulant therapy.1 The effect of anticoagulant withdrawal during Soliris treatment has not been studied.1